>>> HEB US : Reports New Evidence Based Potential of Ampligen Against Ebola Viru

--> HEB +8.48% pre open

Reports New Evidence Based Potential of Ampligen Against Ebola Virus Disease 

reported today a new peer reviewed publication entitled, "The Quest for Effective Ebola Treatment; Ebola VP35 is an Evidence-Based Target for dsRNA Drugs" in the Nature Group's current issue of Emerging Microbes and Infections (October 29, 2014). This publication was authored by affiliates of Hemispherx. The publication provides an illustration of the crystallographic coordinates of a truncated VP35 complex with dsRNA.

Death from Ebola virus (EBOV) infection is associated with markedly impaired coagulation and innate immunity cascades, increased production of pro-inflammatory cytokines, profound immune suppression resulting in peripheral T lymphocyte apoptosis, and a lack of adaptive immunity (Fields Virology 923-956, 2013). By contrast, survivors of infection by EBOV develop an effective immune response with the production of EBOV neutralizing antibodies. Early events in EBOV infection influence the patient's ability to develop an effective immune response. The success of EBOV replication is dependent on viral inhibition of initial innate immune responses to infection. Disarming innate immune responses is a common mechanism employed by highly pathogenic human viruses, including those of the influenza and coronavirus families (Antiviral Res 100:615, 2013). EBOV is one of the more successful of the emerging highly pathogenic viruses in evasion of innate immune mechanisms.

VP35 is a multifunctional major virulence protein that is indispensable for EBOV replication. Double-stranded RNA (dsRNA) is a necessary component of viral replication, which initiates systemic signaling cascades that normally activate interferon (IFN) regulatory factors leading to the production of IFN-a/(type I IFNs). VP35 inhibition of dsRNA effectively disarms essential components of the innate immune response.

>>> US Early premarket gappers

Early premarket gappers
Gapping up: PDII +92%, LAKE +36.1%, APT +15.5%, MOBL +11.7%, ALU +10.9%, LOPE +10%, LOPE +10%, FLTX +9.2%, IBIO +8.4%, FORM +8.2%, FORM +8.2%, NVAX +8.1%, QTM +8%, HOS +7.5%, HOS +7.5%, CJES +6.3%, CBSO +5.5%, TTWO +5.5%, RNG +5.1%, BBSI +5%, PPC +4.5%, AMAG +4.4%, V +3.9%, ACHC +3.8%, CAVM +3.8%, LVLT +3.6%, ALDW+3.6%, TASR +3.5%, ESV +3.3%, JDSU +3.3%, PBR +3.2%, SLCA +3.1%, CEMP +3%, ARRS +3%, LLL +3%, FFIV +2.9%, NCIT +2.9%, CAR +2.9%, CRUS +2.6%, CLD +2.6%, VPRT +2.6%, MA +2.5%, MA +2.5%, CALX +2.4%, DWA +2.4%, MMYT +2.4%, IRM +2.3%, IQNT +2.1%, MET +1.8%, NE +1.8%, NEWP +1.8%, VECO +1.8%, OCN +1.6%, DRIV +1.4%, SPRT +1.4%,EQIX +1.3%, LNC +1.3%, LOCK +1.2%, GBX +1.2%, MDXG +1.2%, NGD +1.2%, INVN +1.1%, ARII +1.1%, NEO +1.1%, ORN +1.1%, EPD +1.1%, QUIK +1%

Gapping down: AFOP -17.2%, GLUU -15%, PRXL -13.9%, WTW -11.6%, PEIX -11.1%, ISIL -10.3%, ATML -10.1%, RGR -9.7%, ARAY -9.7%, AUDC -8.6%, TRLA -6.5%, ASGN -6.4%, Z -5.9%, BGC -5.4%, WSTL -4.8%, WES -4.5%, TGB -4.3%, SFLY -4.1%, TEX -3.5%, AKAM -3.5%, DB -3.4%, SIMO -3.1%, OII -3%, STO -3%, OII -3%, SDRL -2.9%, RRC -2.8%, KRFT -2.8%,CMRX -2.7%, SWHC -2.7%, CLF -2.7%, RIG -2.7%, HBI -2.7%, AUY -2.6%, FMC -2.6%, MDC -2.5%, UBS -2.3%, RRTS -2.3%, SAP -2%, O -2%, WLL -2%, AEM -1.7%, RIO -1.6%, RDS.A -1.6%, BP -1.5%, AHL -1.4%, BIDU -1.4%, MO -1.2%, TWTR -1.1%, RJF -1.1%, MDAS -1%, CGI -1%, GG -1%, K -1%

>>> Walter Energy beats by $0.03, reports revs in-line; guides FY14

Walter Energy beats by $0.03, reports revs in-line; guides FY14 

Reports Q3 (Sep) adj. loss of $1.58 per share, $0.03 better than the Capital IQ Consensus Estimate of ($1.61); revenues fell 27.7% year/year to $329.5 mln vs the $330.37 mln consensus, reflecting a decrease in average met coal selling prices of $22.57 per metric ton ("MT") and a decline in met coal sales of 0.5 million metric tons ("MMTs"). Third quarter results also reflected a reduction in met coal cash cost of sales of $22.04 per ton and a 24% reduction in selling, general and administrative ("SG&A") expenses.
adj. EBITDA $0.2 mln vs. $21.3 mln lat year.

Outlook

The Company expects full-year 2014 met coal production of ~9.5 MMTs, within the range previously provided by the Company. Cash cost of sales per ton for the Company's Alabama underground mines is expected to average approximately $96 per MT for the full year, down from the Company's previous target of approximately $100 per MT. Full-year 2014 met coal sales volumes are expected to total ~ 10.0 MMTs, within the previously provided range.

>>> Elizabeth Arden beats by $0.10, reports revs in-line; reiterates its comment

Elizabeth Arden beats by $0.10, reports revs in-line; reiterates its comments regarding the outlook for fiscal 2015

Reports Q1 (Sep) loss of $0.43 per share, $0.10 better than the Capital IQ Consensus Estimate of ($0.53); revenues fell 20.5% year/year to $273.1 mln vs the $275.07 mln consensus.
  • Net sales of the Company's North America and International segments declined by 23% and 17% (at constant currency rates), respectively. These sales declines were expected and reflect continued proactive tightening of distribution globally, particularly of Elizabeth Arden branded products, in an effort to improve pricing and gross margins, and lower sales of celebrity fragrances, which primarily impacted the Company's North American business.
  • The Company reiterates its comments regarding the outlook for fiscal 2015. Specifically, the Company expects a modest improvement in adjusted earnings for fiscal 2015 over the prior year with continued improvement in fiscal 2016, and continues to expect the following.

>>> Mosaic misses by $0.05, misses on revs (42.70)

Mosaic misses by $0.05, misses on revs (42.70)
Reports Q3 (Sep) earnings of $0.54 per share, $0.05 worse than the Capital IQ Consensus Estimate of $0.59; revenues rose 17.9% year/year to $2.25 bln vs the $2.31 bln consensus.

Highlights:
  • Phosphate results- Average DAP Selling Price $461, 3Q14 guidance- $440 to $470; actual sales volume 3.3 mln tonnes, 3Q14 guidance- 3.3 to 3.6 mln tonnes
  • Potash results- Average MOP Selling Price $291, 3Q14 guidance- $275 to $295, actual sales volume 1.8 mln tonnes, 3Q14 guidance 1.8 to 2.0 mln tonnes.

Guidance:
  • Total sales volumes for the Phosphates segment are expected to range from 2.5 to 2.8 mln tonnes for Q4 r of 2014, compared to 3.4 mln tonnes last year. Mosaic's realized DAP price, FOB plant, for Q4 is estimated to range from $430 to $450 per tonne.
  • Total sales volumes for the Potash segment are expected to range from 2.0 to 2.3 mln tonnes for Q4 of 2014, compared to 1.9 mln tonnes last year. Mosaic's realized MOP price, FOB plant, for Q4, is estimated to range from $275 to $295 per tonne.

>>> Pitney Bowes beats by $0.05, reports revs in-line; guides FY14 EPS in-line;

Pitney Bowes beats by $0.05, reports revs in-line; guides FY14 EPS in-line; reaffirms revenue growth range 

Reports Q3 (Sep) earnings of $0.51 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $0.46; revenues rose 2.3% year/year to $941.64 mln vs the $942.7 mln consensus.
  • Co issues in-line guidance for FY14, sees EPS of $1.85-1.92, excluding non-recurring items, vs. $1.86 Capital IQ Consensus Estimate.
  • Co reaffirms revenue, excluding the impacts of currency, to be in the range of +1-3% yr/yr.

>>> ConocoPhillips beats by $0.10

ConocoPhillips beats by $0.10

Reports Q3 (Sep) adj earnings of $1.29 per share, $0.10 better than the Capital IQ Consensus Estimate of $1.19.
  • Third-quarter production of 1,473 MBOED from continuing operations, excluding Libya, represents four percent growth year-over-year when adjusted for downtime. Outlook:
  • "The company is on track to meet its previously stated growth target of 3 to 5 percent volume and margin growth in 2014. Full-year 2014 production from continuing operations, excluding Libya, is expected to be approximately 1,525 to 1,535 MBOED. Fourth-quarter 2014 production guidance for continuing operations, excluding Libya, is being adjusted to reflect anticipated impacts from the absence of ramp gas sales from APLNG to a third-party LNG project, temporary third-party infrastructure constraints in Malaysia and value-driven ethane rejection in the Lower 48. Fourth-quarter production guidance is 1,545 to 1,575 MBOED.
  • ConocoPhillips expects to release guidance on its 2015 capital expenditures in December. In addition, the company plans to host an Analyst Meeting in New York on April 8, 2015, with additional details to be provided in early 2015.

>>> Johnson Controls beats by $0.03, misses on revs; guides Q1 EPS in-line (midp

Johnson Controls beats by $0.03, misses on revs; guides Q1 EPS in-line (midpoint below)
Reports Q4 (Sep) earnings of $1.04 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus Estimate of $1.01; revenues rose 2.6% year/year to $10.98 bln vs the $11.18 bln consensus.

Co issues in-line guidance for Q1, sees EPS of $0.74-0.77 vs. $0.77 Capital IQ Consensus Estimate.

Johnson Controls will provide full fiscal year 2015 guidance at its annual New York analyst day on Dec. 2, 2014.

"We believe initiatives to improve the profitability of our businesses continue to gain momentum. Our 2014 results provide a foundation that we believe will position us to deliver record sales and earnings in 2015."